Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
Clinically amelanotic lentigo maligna often resembles an inflammatory lesion rather than a melanoma in situ. We present two cases of extensive amelanotic lentigo maligna presenting as gradually enlarging erythematous patches on the faces of women following incomplete excisions of lentigo maligna. Because of their site and size, therapeutic options were limited; the lesions have, however, resolved (clinically and histologically) following the topical application of 5% imiquimod cream. We discuss the rationale for the use of imiquimod in the treatment of lentigo maligna.
Powell
Ann-Marie
AM
Skin Tumor Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom.
Russell-Jones
Robin
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000077271:Imiquimod; D008875:Middle Aged; D009824:Ointments; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D009824:Ointments; D000077271:Imiquimod